Moreover, we observed that the CD8A/CD274 two-genes signature was superior to two previously published gold-standard signatures.16 The CD8A/CD274 signature was also validated in a public data set which involves NSCLC, head and neck, melanoma treated with anti PD1 or PD-L1 mAb. This evidence concerns the gene CD8A and non-small cell lung carcinoma.